Biotech Candidates
Biotech Candidates
Biotech Candidates — May 29, 2026
Overview
Biotech bifurcation deepened. LLY extended to $1,105 (RSI 69.6, +18.4% 30D, near ATH -3.8%) — the GLP-1 thesis keeps expanding. REGN is the new crisis: $614.78, RSI 27.3, approaching capitulation (-12.9% 30D, -8.9% vs SMA20) — golden cross barely intact. CRSP staged a surprising recovery to RSI 60.2 at $56.18 (+11.9% 7D, +7.9% vs SMA20) — still death cross but momentum improving. ISRG continues deteriorating: $424.64, RSI 40, strong-down death cross, -7.2% 30D. ABBV stabilized at $217.72, RSI 61.6 (death cross, up trend). AMGN softened: $336.79, RSI 50.6, weak-down. GILD flat: $134.43, RSI 51.9. VRTX upgraded to strong-up: $447.54, RSI 57.7, +4.7% 30D, golden cross. NTLA recovering: $14.07, RSI 54.8, +8.7% 7D. TMO improved: $492.51, RSI 62.3, +8.7% 7D, +7.3% vs SMA20.
| Signal | Reading |
|---|---|
| Overall | 🟡 Biotech mixed — LLY/VRTX extending; REGN at RSI 27 is the capitulation watch; CRSP surprising recovery |
| Key insight | REGN at RSI 27.3 is now in extreme oversold territory — the deepest oversold in this group. Watch for RSI 25 floor signal before staged entry |
Candidates
| Ticker | Price | RSI | Trend | 7D | 30D | 52wkHi | Signal | Take |
|---|---|---|---|---|---|---|---|---|
| LLY | $1,105.00 | 69.6 | strong-up | +5.6% | +18.4% | -3.8% | GC | GLP-1 thesis extending. +8.8% vs SMA20. Near ATH. Hold with trailing stops. |
| VRTX | $447.54 | 57.7 | strong-up | +2.5% | +4.7% | -11.9% | GC | Upgraded to strong-up. +2.6% vs SMA20. Golden cross confirmed. |
| ABBV | $217.72 | 61.6 | up | -0.3% | +3.0% | -11.1% | DC | Stabilized near RSI 62. +3.7% vs SMA20. Death cross. Holding range. |
| AMGN | $336.79 | 50.6 | weak-down | -1.0% | -2.0% | -13.9% | GC | Softening. +1.7% vs SMA20. Golden cross intact. RSI 51 neutral. |
| GILD | $134.43 | 51.9 | weak-down | +2.3% | +2.7% | -14.5% | GC | Flat. +1.2% vs SMA20. Golden cross. Needs catalyst. |
| TMO | $492.51 | 62.3 | weak-up | +8.7% | +2.8% | -23.5% | DC | Recovery signal. +7.3% vs SMA20. Death cross. RSI bouncing from 40 lows. |
| CRSP | $56.18 | 60.2 | up | +11.9% | +7.3% | -28.4% | DC | Surprising bounce. +7.9% vs SMA20. Death cross. Watch for trend flip. |
| NTLA | $14.07 | 54.8 | strong-up | +8.7% | +4.4% | -50.2% | GC | Recovering. +5.3% vs SMA20. Golden cross. Still -50.2% from ATH. |
| MRNA | $47.19 | 44.2 | weak-down | +0.2% | +2.7% | -20.8% | GC | Drifting. -2.9% vs SMA20. Golden cross. No catalyst. |
| ISRG | $424.64 | 40.0 | strong-down | -3.6% | -7.2% | -29.7% | DC | Continuing deterioration. -3.1% vs SMA20. Death cross. -14.4% 3M. |
| REGN | $614.78 | 27.3↓ | down | -2.5% | -12.9% | -25.1% | GC | EXTREME OVERSOLD. RSI 27.3. -8.9% vs SMA20. Golden cross still intact. Watch RSI 25. |
Action Matrix
| Action | Stocks | Why |
|---|---|---|
| 🔒 HOLD | LLY | GLP-1 runway intact. RSI 70 strong-up — hold with SMA20 trailing stops |
| ✅ STRONG BUY | REGN | RSI 27.3 — extreme oversold approaching capitulation. Golden cross barely intact. Stage entries |
| 📈 ACCUMULATE | VRTX | Upgraded to strong-up GC. RSI 58, +4.7% 30D. Clean entry zone |
| 🔍 WATCH | TMO | RSI 62 bounce from 40 lows. Death cross overhead — watch SMA200 reclaim ($451) |
| 🔍 WATCH | CRSP | RSI 60 is a surprising recovery from RSI 47. Death cross — needs trend confirmation |
| 🔒 HOLD | AMGN, GILD | Stable golden cross anchors. RSI 50-52 neutral — hold, don't add aggressively |
| ❌ DON'T BUY | ISRG | Still deteriorating. -14.4% 3M, death cross, RSI 40. Wait for RSI 30 floor |
| ❌ DON'T BUY | MRNA | Drifting. -20.8% from ATH. Golden cross losing momentum. |
What Changed vs 05/23
REGN deteriorated further to RSI 27.3 — now in extreme oversold territory (from RSI 31.9). CRSP staged a surprise +11.9% 7D bounce, RSI 47→60. VRTX upgraded to strong-up golden cross. TMO recovering with +8.7% 7D. ISRG continues weakening. ABBV held stable rather than extending.
Key Discoveries
| Discovery | Implication |
|---|---|
| REGN RSI 32→27 while CRSP RSI 47→60 | Biotech divergence is stock-specific drug catalysts, not sector rotation — no broad-basket strategy works |
| VRTX upgraded to strong-up GC | Vertex cystic fibrosis franchise re-accelerating — non-GLP1 biotech thesis still has sub-winners |
| TMO RSI 40→62 in one week | Lab equipment / CRO demand signals may be bottoming — if confirmed, broader biotech thesis improving |
Open Questions
- REGN at RSI 27.3: is Dupixent competition (Astegolimab from RHHBY?) or macro rotation? Watch Q2 guidance for thesis check.
- CRSP RSI 60 bounce: genuine gene-editing catalyst or short-cover? Watch for death cross flip.
- ISRG at RSI 40: does the surgical robotics thesis need a hospital capex environment to recover?
Related
10 eventsNo direct external sources are attached to this read.